U2AF1 and acute myeloid leukemia: Historically, AML patients with gene mutations related to spliceosome complex, including U2AF1 were considered as intermediate risk, but with recently updated European LeukemiaNet (ELN) 2022 recommendations, these patients are now considered adverse risk based on associated inferior outcomes [7].